Table 1.
Antiretroviral therapy distribution, overall sample, by therapy group.
Table 2.
Sociodemographic and clinical characteristics at baseline, overall sample.
Table 3.
Status at end of observation period, overall sample, by treatment group.
Fig 1.
Kaplan-Meier curve for two-drug combinations versus triple therapy: a) time to discontinuation), b) switch due to virologic failure, c) switch due to toxicity.
TT: triple therapy; 2DC: two-drug combination.
Table 4.
Final Cox model for two-drug combinations versus triple therapy time to discontinuation, switch due to virologic failure and switch due to toxicity, overall sample.
Table 5.
Antiretroviral therapy distribution within dolutegravir containing therapy sub-sample, by treatment group.
Table 6.
Antiretroviral therapy distribution within suppressed at baseline sub-sample, by treatment group.
Fig 2.
Adjusted hazard ratio for two-drug combinations versus triple therapy forest plot, by sample and endpoint.
DTG: dolutegravir; 2DC: 2 drug combinations; TT: triple therapy.